Allison Nance

Biography

Allison Nance brings to Jounce over two decades of experience in global regulatory affairs with expertise in the development and licensing of drugs, biologics, medical devices and diagnostics. Mrs. Nance joined Jounce in May 2016 from Celgene, where she served as an executive director and member of the regulatory affairs leadership team with oversight of the early development portfolio for both the Hematology & Oncology and Inflammation & Immunology franchises. Her responsibilities included serving on company governance committees and joint development committees established for external biopharmaceutical collaborations. She was also the lead regulatory strategist for biomarkers and companion diagnostics supporting Hematology & Oncology programs and a member of joint steering committees for diagnostics partnerships. Mrs. Nance showed particular interest in promoting adoption of expedited regulatory programs for drugs and biologics intended to treat serious conditions and initiatives supporting personalized medicine. Prior to joining Celgene, Mrs. Nance served as the regulatory head of the Americas for GE Healthcare Medical Diagnostics and, prior to GE, held various positions in regulatory affairs at Roche and Baxter BioScience.

Research Interest

Allison Nance brings to Jounce over two decades of experience in global regulatory affairs with expertise in the development and licensing of drugs, biologics, medical devices and diagnostics. Mrs. Nance joined Jounce in May 2016 from Celgene, where she served as an executive director and member of the regulatory affairs leadership team with oversight of the early development portfolio for both the Hematology & Oncology and Inflammation & Immunology franchises. Her responsibilities included serving on company governance committees and joint development committees established for external biopharmaceutical collaborations. She was also the lead regulatory strategist for biomarkers and companion diagnostics supporting Hematology & Oncology programs and a member of joint steering committees for diagnostics partnerships. Mrs. Nance showed particular interest in promoting adoption of expedited regulatory programs for drugs and biologics intended to treat serious conditions and initiatives supporting personalized medicine. Prior to joining Celgene, Mrs. Nance served as the regulatory head of the Americas for GE Healthcare Medical Diagnostics and, prior to GE, held various positions in regulatory affairs at Roche and Baxter BioScience.